Because Hehe Biotechnology is committed to early screening of cancer, it has broken through ctDNA detection and noise reduction technology.
Release date: 2016-12-02 Today, "early detection, early diagnosis, early treatment" is still the most effective means for humans to fight cancer. As the cost of gene sequencing continues to decline, more and more researchers and startups are investing in the development and application of ctDNA detection technology. For example, 36æ°ª previously reported startups U-Tech, Ankeji, Kyrgyzstan Inga, pan-sub, etc. The ctDNA test is expected to be more efficient and convenient for early detection and diagnosis of cancer. The development of this technology is attracting continued attention in the capital market. Established in March 2016, Shenzhen Yinhe Biotechnology Co., Ltd. is committed to popularizing early tumor screening technology in asymptomatic populations. It is hoped that ctDNA technology will be used to detect very early cancerous changes, so as to eliminate or control it in time. The early screening principle of cancer based on ctDNA detection technology is not complicated, but it faces three challenges. Dr. Liu Chaojun, head of the research and development department of Hebi, said in an interview with 36æ°ª that the sensitivity and accuracy of ctDNA detection technology, the baseline based on large sample database, and the intervention after early detection are three problems that need to be solved for early cancer screening. . In fact, the goal of increasing sensitivity and accuracy has already placed a fairly high demand on startups. Because ctDNA is very low in peripheral blood, it is usually only a few thousandths, and for very early precancerous lesions, the ctDNA content may be as low as one in ten thousand. Therefore, to accurately detect, the technical requirements are very high. In addition, detection techniques also need to consider the issue of background noise. For example, NGS high-throughput sequencing itself has an error of one thousandth, so the impact of this error on ctDNA detection results must be eliminated. In terms of detection sensitivity and accuracy, the breakthrough of Hebi Bio is mainly because the TNR-ctDNA technology developed by the company can eliminate the noise existing in the ctDNA detection process. "TNR-ctDNA has achieved triple noise reduction in sample preparation, sequencing, genetic information, etc., effectively improving the sensitivity and accuracy of detection technology." Liu Chaoyu said 36æ°ª, the sensitivity of TNR-ctDNA has reached Three-tenths of a percent, "We are working hard to make the sensitivity reach one in ten thousand." In addition to the high detection sensitivity and accuracy required, establishing a baseline for the Chinese population is equally important for early detection and prevention of cancer. Liu Chaoyu said that because Hebi has done a lot of work on baseline research, through the cooperation with a number of top three hospitals, it has completed the testing and research of more than 1,000 Chinese population samples, and officially released China on November 26, 2016. Healthy population cfDNA baseline version 1.0. At present, Hebi Bio has begun to collect more samples, including high-risk groups and cancer patients, comparative research, and constantly improve the database. It is expected to launch a baseline 2.0 version containing high-risk populations and cancer patients by the end of 2017. As for the intervention solution after the early screening of tumors, Lei Junxiong, a bio-COO company, said that the company will mainly cooperate with hospitals, health management companies, and immunotherapeutics companies to provide corresponding solutions. Integral itself will focus on the development and application of tumor screening technology. On the whole, Yihe Bio is still in the stage of technology research and development. The company's team members are mainly from Stanford University, Rice University, Hong Kong University, and the Chinese University of Hong Kong. Since the establishment of the company in March this year, it received an angel investment of 10 million yuan. Lei Junxiong said that the company has begun to seek A round of financing. Source: Liu Yong Fruit juice drinks is a beverage made of fruit juice products obtained by physical methods such as pressing, centrifugation and extraction. Fruit juice retains most of the nutrients in the fruit, such as vitamins, minerals, sugar and pectin in dietary fiber. Often drinking fruit juice can help digestion, moisten the intestines and supplement the lack of nutrients in the diet. Juice Drinks,Honey Tea,Honey Citron Tea,Goji Berry Juice Xi'an Gawen Biotechnology Co., Ltd , http://www.seoagolyn.com
There are two kinds of fruit juice: pure fruit juice and compound fruit juice. As far as pure fruit juice is concerned, it can be divided into two types: one is to directly use the original juice, and the other is to dehydrate the freshly squeezed fruit juice first, and then add water to reduce it into concentrated fruit juice. Most pure fruit juices are concentrated. AGOLYN offers various flavors of honey tea, such as honey Citron tea etc.